2,912 results on '"DiPersio, John F."'
Search Results
152. Data from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
153. Supplementary Figure 1 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
154. Suppl Figure 1 from VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival
155. Supplementary Figure 3 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
156. Supplementary Methods from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
157. Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
158. A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome
159. Streptavidin-Drug Conjugates Streamline Identification of Optimal Toxic Payloads for Antibody-Based Hematopoietic Stem Cell Transplantation Conditioning
160. Conditioning with Fully Ablative Antibody-Drug Conjugates Enables Hematopoietic Stem Cell Transplantation with Potent Antileukemia Activity
161. Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia
162. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia
163. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
164. Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients
165. [18F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility
166. Application of CXCR4 Inhibitors in Leukemia
167. Relevance and Clinical Implications of Tumor Cell Mobilization in Autologous Transplantation of Multiple Myeloma and Non-Hodgkin’s Lymphoma
168. Genomic landscape ofTP53-mutated myeloid malignancies
169. Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide
170. Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice
171. Flotetuzumab and other T-Cell Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells
172. S100A9 up-regulated by IFNGR signaling blockade functions as a novel GvHD suppressor without compromising GvL in mice
173. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis
174. Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience
175. The Dual PI3Kdg Inhibitor Duvelisib Potently Inhibits Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function
176. Modeling Flotetuzumab-Associated CRS in AML Using in Vitro and in Vivo Preclinical Models
177. The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study
178. Fully Myeloablative Antibody-Drug Conjugates Condition for Hematopoietic Stem Cell Transplantation and Provide Durable Antileukemia Benefit
179. JAK1 Inhibition during CAR T-Cell Treatment Does Not Affect CAR T-Cell Proliferation, Persistence, or Function
180. Optimized Small Molecule VLA-4 Inhibitors for Hematopoietic Stem and Progenitor Cell Mobilization
181. Re-Sensitization of Allogeneic T Cell Resistant Murine AML with Pegylated IFN-Gamma
182. Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant
183. Despite Use of Upfront Plerixafor and G-CSF, Daratumumab Exposure Reduces Stem Cell Mobilization in Patients with Multiple Myeloma
184. Cost-Effectiveness Analysis of Motixafortide Versus Plerixafor in Stem Cell Mobilization for Autologous Transplantation in Patients with Multiple Myeloma
185. Streptavidin-Drug Conjugates Streamline Identification of Optimal Toxic Payloads for Antibody-Based Hematopoietic Stem Cell Transplantation Conditioning
186. Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse
187. Duvelisib for Critically-Ill Patients with COVID-19 Disease: An Investigator-Initiated, Randomized, Placebo-Controlled Double-Blind Pilot Trial
188. A Phase I Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) As a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapy in Sickle Cell Disease
189. A Phase 1b Dose Expansion Study Evaluating Safety, Preliminary Anti-Tumor Activity, and Accelerated T Cell Reconstitution with NT-I7 (Efineptakin Alfa), a Long-Acting Human IL-7, Administered Following Tisagenlecleucel in Subjects with Relapsed/Refractory Large B-Cell Lymphoma
190. Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell–Associated Neurotoxicity Syndrome
191. Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective
192. Allogeneic Transplantation for Myelodysplastic Syndromes
193. Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells
194. S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in mice
195. Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid Leukemia
196. Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation
197. Role of Hematopoietic Stem Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndrome
198. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial
199. Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen
200. Advances in stem cell mobilization
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.